Literature DB >> 17956532

Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha.

Yong-Guang Jiang1, Yong Luo, Da-lin He, Xiang Li, Lin-lin Zhang, Tao Peng, Ming-Chuan Li, Yun-Hua Lin.   

Abstract

OBJECTIVES: Epithelial-mesenchymal transition (EMT) is an important process in tumor development, and several studies suggest that the Wnt/beta-catenin signal pathway may play an important role in EMT. However, there is no direct evidence showing that the Wnt/beta-catenin pathway actually determines the EMT induced by an exogenous signal. Our previous research has successfully proved that overexpression of hypoxia-inducible factor-1alpha (HIF-1alpha) could induce EMT in LNCaP cells, but not in PC-3. The present study aims to determine whether the signal of HIF-1alpha for inducing prostate cancer cells to undergo EMT might possibly pass through the Wnt/beta-catenin pathway.
METHODS: Epithelial-mesenchymal transition associated proteins were detected in several human prostate carcinoma cell lines by Western blot, and then we distinguished the EMT positive cell lines from the EMT negative cell lines. Furthermore, we evaluated the possible correlation between potency of invasiveness and proliferation among these cell lines with different characteristics of EMT using Matrigel transwell and thiazolyl blue tetrazolium bromide (MTT) assays. Finally, the different expression of some critical proteins and genes in Wnt/beta-catenin signaling pathway were analyzed by Western blot and reverse transcription-polymerase chain reaction (RT-PCR) in these cells with different characteristics of EMT.
RESULTS: Among several prostate cancer cell lines, PC-3, LNCaP and PC-3/HIF-1alpha are EMT negative cell lines, whereas LNCaP/HIF-1alpha and IA8 have undergone the EMT process. EMT positive cells (LNCaP/HIF-1alpha and IA8) exhibit much stronger potency of invasiveness and proliferation than those of PC-3 and LNCaP, which belong to EMT negative cells. Interestingly, although PC-3/HIF-1alpha had not completed the EMT process, it still displayed stronger potency of invasion and proliferation, resembling EMT positive cells. The protein expression level of total glycogensynthase kinase 3beta (GSK-3beta) and phospho-GSK-3beta in LNCaP/HIF-1alpha, IA8 and PC-3/HIF-1alpha cells significantly decreased; however, the relative ratios of p-GSK3beta/t-GSK3beta in LNCaP/HIF-1alpha, IA8 and PC-3/HIF-1alpha cells were significantly higher than PC-3 and LNCaP. Consistently, beta-catenin protein expression increased in LNCaP/HIF-1alpha and IA8 cells, but not in PC-3/HIF-1alpha; RT-PCR confirmed these results, except for the enhanced transcription activity of beta-catenin mRNA in PC-3/HIF-1alpha.
CONCLUSION: Our data suggests that activation of the Wnt/beta-catenin signaling pathway correlates with the characteristic of EMT and potency of invasiveness and proliferation. This may be the critical factor that directly controls the process of EMT induced by HIF-1alpha in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17956532     DOI: 10.1111/j.1442-2042.2007.01866.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  81 in total

1.  Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies.

Authors:  Lindsay J Talbot; Syamal D Bhattacharya; Paul C Kuo
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

2.  Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process.

Authors:  Leonardo Freire-de-Lima; Kirill Gelfenbeyn; Yao Ding; Ulla Mandel; Henrik Clausen; Kazuko Handa; Sen-Itiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

3.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

4.  RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin.

Authors:  Shiguang Cao; Ruiying Sun; Wei Wang; Xia Meng; Yuping Zhang; Na Zhang; Shuanying Yang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

5.  Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor.

Authors:  Y-H Cui; Y Suh; H-J Lee; K-C Yoo; N Uddin; Y-J Jeong; J-S Lee; S-G Hwang; S-Y Nam; M-J Kim; S-J Lee
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

6.  DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype.

Authors:  Aparna Mitra; Mitchell E Menezes; Lalita A Shevde; Rajeev S Samant
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

Review 7.  Long non-coding RNAs in cancer invasion and metastasis.

Authors:  Xiao-han Shen; Peng Qi; Xiang Du
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

Review 8.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

9.  Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

Authors:  Wei Chen; Qi-Da Hu; Xue-Feng Xia; Chao Liang; Hao Liu; Qi Zhang; Tao Ma; Feng Liang; Ting-Bo Liang
Journal:  Cancer Biol Ther       Date:  2014-05-06       Impact factor: 4.742

10.  Periostin is up-regulated in high grade and high stage prostate cancer.

Authors:  Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.